The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Abstract
Human cancer is characterized by deficits in antigen-specific immunity and intratumoral CD8+ T cells. On the other hand, inflammatory macrophages and mediators of chronic inflammation are highly prevalent in patients with late-stage cancer. Intratumoral T-cell deficiency and chronic inflammation have been linked independently to a poor prognosis in patients with cancer, and therapeutic approaches to overcome either pathology separately are in clinical testing. The anti-inflammatory cytokine interleukin (IL)-10 suppresses macrophage and proinflammatory Th17 T-cell responses by inhibiting the inflammatory cytokines IL-6 and IL-12/23. Corroborating the anti-inflammatory action of IL-10, deficiency in IL-10 leads to a stimulation of inflammatory responses and inflammatory bowel disease. The anti-inflammatory role of IL-10 fostered the assumption that IL-10 undermines the immune response to cancer. However, mice and humans deficient in IL-10 signaling develop tumors spontaneously and at high rates. Overexpression of IL-10 in models of human cancer or treatment with a pegylated IL-10 (PEG-IL-10) led to tumor rejection and long-lasting tumor immunity. IL-10 stimulates cytotoxicity of CD8+ T cells and the expression of IFN-γ in CD8+ T cells. IL-10–induced tumor rejections are dependent on the expression of IFN-γ and granzymes in tumor-resident CD8+ T cells and the upregulation of MHC molecules. These findings reconcile earlier clinical data, which showed that recombinant IL-10 increased IFN-γ and granzymes in the blood of treated individuals. PEG-IL-10 is therefore a unique therapeutic agent, which simultaneously stimulates antitumor immunity and inhibits tumor-associated inflammation. Cancer Immunol Res; 2(3); 194–9. ©2014 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737 · cited 1×
“Shortly after its cloning, IL-10 was described as a B-cell– derived T-cell growth factor (B-TCGF) for its ability to stimulate CD8þ T cells (11, 28).”
BackgroundThe immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · cited 1×
“Over the past decade, many studies demonstrated that infiltration of T cells is the single most important prognostic factor for the majority of human tumor types (2).”
BackgroundNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“revealed a stunning improvement over each therapy alone, with 53% of patients with melanoma receiving the combined regimen experiencing complete responses (6).”
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039 · cited 1×
“matory diseases in humans are genetically linked to the IL23R gene (24).”
BackgroundBrahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961 · cited 4×
“Cancer Immunol Res; 2(3) March 2014 194”
BackgroundInfluentialFiorentino, D. F., Bond, M. W., & Mosmann, T. R. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.6.2081 · Cited by 2,733
Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor
Glocker, E.-O., Kotlarz, D., Boztug, K., Gertz, E. M., Schäffer, A. A., Noyan, F., Perro, M., Diestelhorst, J., Allroth, A., Murugan, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907206 · Cited by 1,461
Berg, D. J., Davidson, N., Kühn, R., Müller, W., Menon, S., Holland, G., Thompson-Snipes, L., Leach, M. W., & Rennick, D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118861 · Cited by 1,136 · cited 1×
“cancer (9) and humans deficient in IL-10 signaling develop lymphomas at a young age (8); these consequences of IL-10 deficiency provide support for the concept of tumor-promot-”
BackgroundNeutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079 · cited 1×
“a worsened prognosis for patients with cancer (18).”
BackgroundT-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells
Afkarian, M., Sedy, J. R., Yang, J., Jacobson, N. G., Cereb, N., Yang, S. Y., Murphy, T. L., & Murphy, K. M. (2002) · Nature Immunology · doi:10.1038/ni794 · Cited by 1,037
Cited by
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
Ouyang, W., & O’Garra, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.020 · Cited by 1,072
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 714
“Highly expressed by Th17 cells, myeloid DCs, and TAMs [111] following the context-dependent activation of STAT3, auxiliary STATs, and extracellular signal-regulated kinase (ERK) pathways [111], the IL-10 family of cytokines have been reported to block cytotoxic T cell function through the inhibition of APCs [111] and…”
BackgroundCarlini, V., Noonan, D. M., Abdalalem, E., Goletti, D., Sansone, C., Calabrone, L., & Albini, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161067 · Cited by 543
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3024 · Cited by 569
Metadata
- Authors
- Oft, M.
- Affiliations
- Author's Affiliation: ARMO BioSciences, Redwood City, California
- Corresponding author
- Oft, Martin
- ORCID
- Oft, Martin
- Venue
- Cancer Immunology Research
- Published
- 2014-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 194-199
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W2114872225
- Cited by
- 322
- References
- 47
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 43 · 2023: 35 · 2022: 35 · 2021: 41 · 2020: 41 · 2019: 23 · 2018: 22 · 2017: 14 · 2016: 19 · 2015: 4
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- IL-10, antitumor immunity, tumor inflammation, CD8+ T cells, interferon-gamma, granzymes, MHC expression, tumor rejection, IL-10 deficiency, interleukin-6, IL-12/23, Th17 cells, tumor-associated macrophages, cancer immunotherapy
- MeSH terms
- Animals, Humans, Inflammation, Interferon-gamma, Macrophages, Neoplasms, Polyethylene Glycols, Signal Transduction, Gene Expression Regulation, Neoplastic, Interleukin-10, CD8-Positive T-Lymphocytes, Mice, Granzymes, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity. https://app.cochat.ai/papers/10.1158/2326-6066.cir-13-0214
- The paper
- Oft, M. (2014). IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-13-0214
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.